Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PS315 inhibits the full-length and catalytic domain constructs of PKCζ (IC50=10 μM) and PKCη (IC50=30 μM). PS315 has anti-cancer activity. PS315 is a derivative of PS48 and is an allosteric PKC inhibitor by binding to the PIF-pocket of aPKC and inducing d
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
ターゲット&IC50 | PKCζ:10 μM, PKCη:30 μM |
In vitro | PS315, by attaching to the PIF-pocket, prompts a shift in the active site residue Lys111, effectively inhibiting aPKCs through an allosteric impact on the enzyme's catalytic process. A pre-treatment of U937 cells with 5 μM PS315 results in a 74% reduction in TNF-α-induced NF-κB activation, with total inhibition achieved at 10 μM PS315. The allosteric inhibitor PS315, along with the N-terminal region of aPKC, directly influences the PIF-pocket on-off switch[1]. |
分子量 | 362.85 |
分子式 | C23H19ClO2 |
CAS No. | 1221964-50-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PS315 1221964-50-6 Chromatin/Epigenetic Cytoskeletal Signaling PKC PS 315 PS-315 Inhibitor inhibitor inhibit